Cargando…
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
BACKGROUND: Tumor infiltrating lymphocytes (TILs) are considered in the prognosis of breast cancer (BC) patients. Here, we investigated the prognostic/predictive effect of TILs in patients treated in the frame of four prospective trials with adjuvant anthracycline-based chemotherapy in the pre- and...
Autores principales: | Kotoula, Vassiliki, Chatzopoulos, Kyriakos, Lakis, Sotiris, Alexopoulou, Zoi, Timotheadou, Eleni, Zagouri, Flora, Pentheroudakis, George, Gogas, Helen, Galani, Eleni, Efstratiou, Ioannis, Zaramboukas, Thomas, Koutras, Angelos, Aravantinos, Gerasimos, Samantas, Epaminontas, Psyrri, Amanda, Kourea, Helen, Bobos, Mattheos, Papakostas, Pavlos, Kosmidis, Paris, Pectasides, Dimitrios, Fountzilas, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826267/ https://www.ncbi.nlm.nih.gov/pubmed/26506242 http://dx.doi.org/10.18632/oncotarget.6231 |
Ejemplares similares
-
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016) -
Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes
por: Kotoula, Vassiliki, et al.
Publicado: (2016) -
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study
por: Papaxoinis, George, et al.
Publicado: (2015) -
Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013) -
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study
por: Koutras, Angelos, et al.
Publicado: (2015)